Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...
Abstract: This paper, marks an innovative exploration of robotics, IoT, and telepresence technologies, aiming to create a versatile and user-friendly robot, for remote control and real-time presence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results